Introduction
Apathy is a state of decreased motivation that is characterized by diminished goal-directed behavior, goal-directed cognition, and emotion [1] . Diminished behavior manifests as lack of effort and dependency on others to structure activity. Diminished cognition manifests as a lack of interest in learning new things or in new experiences. Diminished emotion refers to unchanging affect and lack of emotional responsivity to positive or negative events.
Apathy has been commonly reported in various neurological disorders. In a review of the literature, 20-80% of patients manifested apathy in Parkinson's disease (PD), progressive supranuclear palsy (PSP), stroke, or Alzheimer's disease (AD) [2] . The occurrence of apathy is connected to damage of the prefrontal cortex (PFC) and basal ganglia by structural and metabolic neuroimaging studies [3, 4] . In a review of the literature, emotional apathy was related to the orbitomedial PFC and ventral striatum, cognitive apathy was associated with dysfunction of the lateral PFC and dorsal caudate nuclei, and behavioral apathy occurred in damage of the globus pallidus, thalamus, or dorsomedial PFC [5] .
Apathy has been associated with a number of adverse outcomes. First, apathy is associated with poor quality of life (QOL). Apathetic AD patients were found to have low functioning in their activities of daily living [6] . In a geriatric inpatient rehabilitation unit treating stroke and hip fracture, apathy at admission was the second independent variable to predict level of functioning at discharge [7] . Second, apathy is likely to induce distress in caregivers. In AD outpatients, caregiver distress correlated with Neuropsychiatry Inventory-rated apathy [8] . Third, apathy appears to be associated with a poor outcome of illness. In AD outpatients, a faster rate of decline in cognitive function was found in the apathetic patients compared with nonapathetic ones [9] . Fourth, apathy has also been associated with poor response to treatment. In geriatric inpatients, apathy was associated with a lack of participation in rehabilitation [7] . Apathy had a negative impact on diabetes control due to poor adherence to insulin regimen [10] . Finally, the negative impact of apathy appears to heighten healthcare costs and need for care [2] .
Although apathy has been commonly reported in several neurological disorders, its clinical significance in epilepsy has not been clearly identified. As we know, people with epilepsy (PWE) have a high risk of developing psychobehavioral problems including depression, anxiety, psychosis, obsessiveness, and aggression [11] [12] [13] [14] . Those problems were found to be associated with poor QOL [12, 15] . Furthermore, antiepileptic drugs (AEDs) may have specific psychotropic profiles according to the mode of action [16] . Negative psychotropic profiles can reduce compliance with treatment and affect QOL [15, 17] . However, the appearance of apathy in PWE has not been highlighted as a significant behavioral problem. For acknowledging its clinical significance in PWE, we measured the degree of interictal apathy in PWE compared with healthy controls and identified its predictors. We also investigated whether apathy in PWE affected their daily living.
Methods

Participants
We enrolled consecutive patients who had been visiting an epilepsy clinic at Kyungpook National University Hospital since January 2016 and treated with AEDs for at least 1 year. Patients who were 18 to 70 years old, had a current diagnosis of epilepsy, and provided informed consent were included. Epilepsy was diagnosed according to the criteria of the International League Against Epilepsy (ILAE) for seizures and epileptic syndromes [18, 19] . Patients with an intellectual disability or serious medical, neurological, or psychiatric disorders, or other disorders that prevented them from understanding the questionnaire and cooperating with the study procedures were excluded. Patients who had seizure occurrence within 48 h were also excluded. This study recruited age-and gender-matched healthy controls. Most controls were high school or university students, hospital employees, and office workers although some were parents, siblings, offspring, or relatives of the patients. Controls who looked after patients were excluded.
Study design
This study was a case-control study and all participants provided written informed consent before participation. Demographic, socioeconomic, and clinical information were collected by an interview in the clinic, and all data were entered into a computerized file.
The demographic variables were age, gender, and education. The socioeconomic variables were employment status (employed versus unemployed), household income (at least one million Korean won (KRW) per month [equivalent to US$ 900 per month] versus less than one million KRW/month), possession of a driving license (yes versus no) and marital status (married versus divorced, bereaved, or unmarried). The clinical variables were age at onset of epilepsy, duration of epilepsy, type of seizure, epilepsy syndrome, MRI abnormality, history of febrile convulsion, family history of epilepsy, AED year, AED therapy regimen, AED load, gammaaminobutyric acid-ergic (GABAergic) AEDs intake, and degree of seizure control. Epilepsy syndrome was composed of 4 categories: temporal lobe epilepsy (TLE), extraTLE (epilepsy syndromes in which the epileptic attacks originated from the frontal, parietal, or occipital lobes), generalized epilepsy (GE), and unknown syndrome. The AED year indicated the year of AED intake. We divided patients into 3 groups by AED year as follows: 1-9 years, 10-19 years, and 20 years or more. AED regimen was classified as monotherapy or polytherapy according to the number of AEDs the patient was using. AED load was estimated as the sum of the ratios of prescribed daily dose (PDD) versus defined daily dose (DDD; the assumed average daily maintenance dose of the drug when used for its main indication [20] ) for each AED in the subject's treatment regimen [21] . AEDs acting on GABA inhibitory neurotransmission seemed to have sedating profiles including hypersomnia, fatigue, depression, cognitive slowing, weight gain, and apathy [22] . Therefore, we divided AEDs into GABAergic and non-GABAergic AEDs. Barbiturates, benzodiazepines, valproate, gabapentin, tiagabine, and vigabatrin were allocated to GABAergic AEDs. Epilepsy patients were classified into three categories based on the state of their seizure control: uncontrolled epilepsy (UCE), well-controlled epilepsy (WCE), and poorly controlled epilepsy (PCE). UCE (i.e., drug-refractory epilepsy) was defined as an average of more than one seizure per month for 18 months and maximum seizure-free periods of less than 3 months. WCE was defined as freedom from seizures during the preceding year, and PCE was defined as an intermediate degree of seizure control that did not meet the criteria for UCE or WCE [23] . The seizure-control category for each epilepsy patient was determined based on information about seizure frequency obtained from their medical records. The Apathy Evaluation Scale-Self (AES-S) [24] , the Korean version of the Neurological Disorders Depression Inventory for Epilepsy (K-NDDI-E) [25] , the Generalized Anxiety Disorder-7 (GAD-7) [26] , the Epworth Sleepiness Scale (ESS) [27] , the Insomnia Severity Index (ISI) [28] , and the Quality of Life in Epilepsy-10 (QOLIE-10) [29] were completed by patients. The control participants completed the AES-S, K-NDDI-E, and GAD-7.
We identified predictors for interictal apathy in the whole PWE. In addition, because apathy is a slightly different psychopathological construct and involve different brain networks compared to depression, we identified predictors by the presence of depression.
Questionnaires
2.3.1. Apathy Evaluation Scale-Self (AES-S)
The AES was developed to ascertain and quantify apathy within the month prior to the time of the assessment and was specifically designed to provide a detailed exploration of cognitive, behavioral, and emotional aspects of apathy [30] . Clinicians can use 3 versions including AES-Self (AES-S), AES-Informant (AES-I), and AESClinician (AES-C), according to the intended respondent. We used the AES-S. It consists of 18 items and 4 subscales including cognitive, behavioral, emotional, and other subscales. Each item is scored on 4-point Likert scale (1: not at all true, 2: slightly true, 3: somewhat true, 4: very true). The overall AES-S score ranges from 18 to 72. A higher score indicates more severe apathy. The Korean version of the AES-S was validated and the Cronbach's a coefficient is 0.76 [24] .
Korean version of the Neurological Disorders Depression Inventory for Epilepsy (K-NDDI-E)
The K-NDDI-E is a quick, reliable, and validated screening tool for major depressive disorder (MDD) in epilepsy patients [25] . It is a 6-item measure using a 4-point scale (1-4) to evaluate the degree to which an epilepsy patient has been bothered by depressionrelated problems over the previous 2 weeks. The total score ranges from 6 to 24, and higher scores indicate a more intense level of depression. A total score of 12 or more is suggestive of MDD and the Cronbach's a coefficient is 0.898. We determined depressed or nondepressed state by a cutoff score of 11.
Generalized Anxiety Disorder-7 (GAD-7)
The GAD-7 is a self-report questionnaire used for the rapid detection of generalized anxiety disorder (GAD) [26] . It is a 7-item measure using a 4-point scale (0-3) to assess the degree to which a participant has been bothered by anxiety-related problems over the previous 2 weeks. The total score ranges from 0 to 21, and higher scores indicate a more intense level of anxiety. A total score of 7 or more is suggestive of GAD and the Cronbach's a coefficient is 0.924.
Epworth Sleepiness Scale (ESS)
The ESS is widely used to measure the general level of daytime sleepiness [27] . The ESS is comprised of eight questions, each asking about the participant's likelihood of dozing off or falling asleep in a particular situation that is commonly faced in daily life. Respondents use a 4-point scale for each of the eight questions. Higher scores indicate higher subjective sleepiness. The Cronbach's a coefficient is 0.9.
Insomnia Severity Index (ISI)
The ISI is a brief self-report questionnaire that measures the patient's perception of insomnia severity [28] . The ISI comprises seven items and each of the ISI items is rated on a scale of 0-4; the total score ranges from 0 to 28, with a higher score indicating greater insomnia severity. The total ISI scores are divided into four subcategories: 0-7, no clinically significant insomnia; 8-14, subthreshold insomnia; 15-21, moderate insomnia; and 22-28, severe insomnia. A cutoff score of 15 is the threshold for clinically significant insomnia, and a score below 8 indicates remission after treatment. The Cronbach's a coefficient is 0.92.
Quality of Life in Epilepsy-10 (QOLIE-10)
The QOLIE-10 is a 10-item self-administered questionnaire specifically designed to measure QOL in patients with PCE [29] . This measure consists of subscales that address epilepsy effects, mental health, and role functioning, and higher scores indicate better QOL. The Cronbach's a coefficient is 0.843 for the epilepsy effects and role function subscales, and 0.606 for the mental health subscale.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS version 19.0) was used for data analysis. This study has presented a set of descriptive statistics: counts, percentages, means, and standard deviations. Comparisons between groups were made using independent t-tests, Chi-square tests, one-way analyses of variance (ANOVA), or analyses of covariance (ANCOVA). To determine the relationship between various independent variables and the overall AES-S score, Pearson's correlation coefficient was applied. Variables that were significantly correlated with the overall AES-S score were included in multiple linear regression analyses with stepwise selection using entry and exit probabilities of 0.05 and 0.1, respectively. Collinearity statistical analysis was performed to assess collinearity. The level of statistical significance was set at 0.05.
Results
Characteristics of eligible participants
We initially included 292 epilepsy patients, but 52 were excluded for the following reasons: mental retardation (n = 21), refusal to complete the questionnaires (n = 19), severe neurological or other disorders (n = 10), and being older than 70 years of age (n = 2). Finally, 240 patients (mean age: 39.8 AE 12.9 years; 60.4% males) were eligible for the study. In addition, 124 healthy controls (mean age: 39.3 AE 11.4 years; 62.1% males) were also invited in the study. The demographic, socioeconomic, clinical, and psychosomatic characteristics of eligible participants are summarized in Table 1 . The PWE had a lower mean educational level, were less likely to be employed, had a lower mean income, and were less likely to hold a driving license or be married than controls. Concurrent medical disease manifested in 85 patients (35.4%) including diabetes and other endocrine disorders (n = 26), hypertension and other cardiovascular disorders (n = 21), cerebrovascular disease and other neurological disorders (n = 19), orthopedic diseases (n = 13), hemato-oncologic and autoimmune diseases (n = 7), hepatic and gastrointestinal disorders (n = 5), and other medical diseases (n = 8). Partial seizure was noted in 182 patients (75.8%). The most common epilepsy syndrome was TLE, followed by extraTLE, GE, and unknown syndrome. MRI abnormalities were found in 116 patients (48.3%). The most common etiology in brain MRI was hippocampal sclerosis (n = 35), followed by congenital anomalies (n = 21), vascular diseases (n = 20), traumatic injury (n = 19), infection (n = 12) and other diseases (n = 11). The AED year was 11.9 AE 10.1 years (range, 1-50 years). AEDs were taken by 125 patients (52.1%) for 1-9 years, 67 patients (27.9%) for 10-19 years, and 48 patients (20.0%) for 20 years or more. Monotherapy was conducted in 120 patients (50.0%). The AED load was 1.3 AE 1.0 (range, 0.2-4.9). GABAergic AEDs were administered in 121 patients (50.4%). Regarding seizure control, 140 patients (58.3%) manifested WCE, whereas 34 patients (14.2%) manifested UCE. The ESS, ISI, and QOLIE-10 scores were 4.5 AE 3.7 (range, 0-20) and 7.6 AE 6.1 (range, 0-26), and 78.2 AE 17.0 (range, 12.5-100), respectively.
Apathy, depression, and anxiety between patients and controls
The degree of apathy, depression, and anxiety in PWE compared with controls are listed in Table 2 . The mean overall AES-S score of PWE was not different from that of controls. However, that score was significantly higher in patients with UCE than controls (p < 0.01). The mean behavioral AES-S score of PWE was significantly higher than that of controls (p < 0.01). This score was also significantly higher in patients with PCE (p < 0.05) or UCE (p < 0.001), compared with controls. The mean emotional AES-S score was significantly higher in patients with UCE than controls (p < 0.05). People with epilepsy had higher levels of depression and anxiety than controls.
Factors associated with the overall AES-S score
Variables associated with the overall AES-S score by univariate analyses are summarized in Table 3 . The overall AES-S score was higher in patients with low educational level (p = 0.022), no However, GABAergic AED intake was not correlated with the overall AES-S score.
Predictors for the overall AES-S score
Predictors for the overall AES-S score by multivariate analyses are listed in Table 4 . The strongest predictor was the K-NDDI-E score (b = 0.476, p < 0.001), followed by the AED year (b = 0.151, p = 0.008). Stepwise regression produced a two-variable model that explained 26.4% of the variance in the overall AES-S score. The variance inflation factor (VIF) was less than 10 for two variables, which suggested that they exerted independent effects without redundancy. According to the standardized b, the contribution of the K-NDDI-E score to the overall AES-S score was 3.2 times greater than that of the AED year. The difference of the overall AES-S score according to the AED year is illustrated in Fig. 1 . Patients who took AEDs for 20 years or more had a higher degree of apathy compared with those who received AEDs for 1-9 years (p = 0.002).
Predictors for the overall AES-S score in depressed and nondepressed patients by multivariate analyses are documented in Table 5 . In depressed patients, the strongest predictor was age (b = 0.336, p = 0.006), followed by the K-NDDI-E score (b = 0.306, p = 0.011). Stepwise regression produced a two-variable model that explained 23% of the variance in the overall AES-S score. In nondepressed patients, the strongest predictor was the K-NDDI-E score (b = 0.232, p = 0.002), AED year (b = 0.168, p = 0.019), followed by the ISI score (b = 0.163, p = 0.028). Stepwise regression produced a three-variable model that explained 12.1% of the variance in the overall AES-S score.
Relationship between interictal apathy and quality of life
The relationship between interictal apathy and QOL in PWE is described in Fig. 2 . The overall AES-S score was inversely correlated with the overall QOLIE-10 score (p < 0.001).
Discussion
We examined the degree of interictal apathy in PWE compared with healthy controls. The mean overall AES-S score in PWE was similar to that of controls, but the mean overall, behavioral, and emotional AES-S scores in patients with UCE were higher than those of controls. So far, only one study has examined the degree of self-reported apathy in PWE compared with healthy controls. An Italian, hospital-based study investigated apathy in 55 patients with epilepsy [31] . Sixty percent of patients had primary generalized seizure, 63% had WCE, and 85% received AED monotherapy. They found that the overall and subscale AES-S scores of PWE were not different from those of controls. The same results were found in our patients with WCE. However, the Italian study could not identify the degree of apathy in severe epilepsy patients with polytherapy, because only 3 patients were included in this category. Therefore, the benefit of our study was that it elucidated the nature of apathy in patients with severe epilepsy. Another issue that we found was the higher degree of behavioral subscale score among the 4 different subscale scores in PWE than controls. As already noted, behavioral apathy is characterized by a lack of effort and dependency on others to structure activity [1] . Diminished effort produces disability in virtually all essential areas of human functioning. For example, it increases the risk of treatment failure because patients will not initiate or persist in following prescribed medication or intensive treatment programs [7, 10] . Medication compliance will be decreased or appointments will be missed. If such events occur in PWE, their seizures will reappear or be aggravated. We found that the degree of behavioral apathy was the highest in patients with UCE. Thus, clinicians should consider the impact of apathy on seizure control when they treat patients with severe epilepsy. We also reported that emotional apathy existed in patients with UCE. Because inappropriate emotional expression can have harmful effects on familial and social relationships, clinicians also should pay attention to the existence of emotional apathy in patients with severe epilepsy.
We found that the overall AES-S score was associated with a low education level, unemployment, and low household income. As we know, patients with severe epilepsy are less likely to receive an education, and more likely to be unemployed and poor. Therefore, it is a reasonable thought that apathy is associated with sociodemographic variables. The overall AES-S score was also correlated with longer disease duration, longer AED year, polytherapy, and higher dose of AEDs. In this context, we can suggest two possibilities for the occurrence of apathy. That is, not only seizure severity but also long-term exposure to a large amount of AEDs may induce apathy in PWE. We found that the overall AES-S score was associated with depression, anxiety, daytime drowsiness, and insomnia. Depression shares symptoms associated with apathy such as loss of interest, energy, or insight, and psychomotor Table 4 Predictors of the overall AES-S score in people with epilepsy by stepwise linear regression analyses. retardation [32] . Consequently, it is not surprising that apathy is closely related to depression. Furthermore, depressed PWE have been reported to elicit comorbid anxiety and sleep problems [11, 33, 34] . Thus, it is natural that apathy is likely to accompany these psychosomatic symptoms. In contrast to the hypothesis suggested by Ketter et al. [22] , we could not establish a relationship between apathy and GABAergic AEDs. As already mentioned, almost all of our patients exhibiting apathy received AED polytherapy. Therefore, drug interactions may compromise the effect of AEDs on apathy. Further studies to prove this relationship should be conducted with an individual AED. We did not identify any relationship between epilepsy syndrome or MRI abnormality and the overall AES-S score. That means interictal apathy in PWE appears to be produced by long-term AED effect, but not by epilepsy pathology. We reported that the duration of AED intake as expressed by AED year was a major predictor for interictal apathy after controlling for depression in the whole PWE. We found that patients who received AEDs for 20 years or more were more likely to have apathy than those for less than 10 years. This means longterm exposure to AEDs might be a risk factor for the occurrence of interictal apathy. There is good evidence that depression and apathy present independently according to the pathologic substrates. Depression without apathy is common in PD, whereas apathy without depression is common in PSP [35] . Similarly, some responsibility for the occurrence of apathy in PWE may rely on AED intake regardless of comorbid depression. We also found AED year was an important factor for interictal apathy in nondepressed patients. According to the adverse effects of AEDs based on a modified version of the WHO classification, this phenomenon actually approximates to type C adverse effects of AEDs [36] . Type C effects include chronic reactions related to cumulative drug exposure. They can be insidious because of their slow progressive development and some of them recede after discontinuation of the drug, but others can be irreversible [36] . Several adverse effects have been associated with type C effects. Somatic problems such as decreased bone mineral density, weight gain or loss, connective tissue disorders, gingival or hair problems, and visual field loss were representative, but psychobehavioral problems were not identified in this category [36] . As we know, psychobehavioral problems are more important to determine QOL than somatic problems including epileptic attacks in PWE [12, 15] . We also found that interictal apathy in PWE was closely associated with their QOL in this study. Thus, we emphasize apathy as an underrecognized behavior in PWE that clinicians should be alert to.
We found both of disease duration and AED year were well correlated with the overall AES-S score. As we can guess, a longer duration of epilepsy is likely to have a longer duration of AED intake. However, in multivariate analyses, disease duration was not selected as a significant factor for apathy. To clarify the reason, we conducted multivariate analyses not including AED year as a variable. Then we found only depression was selected as a significant factor for interictal apathy. So we can suggest a longer disease duration may produce apathy by inducing depression, but AED year may produce apathy regardless of depression.
The pathogenic mechanism of apathy associated with AEDs was not introduced. As already noted, behavioral apathy is associated with dysfunction of the globus pallidus, thalamus, or dorsomedial PFC [5] . These regions consist of executive circuits and maintain the ability to generate and sustain purposeful goal-directed behavior [37] . Some AEDs resulted in dysfunction of these regions when cognitive tasks were given. Executive dysfunction with topiramate (TPM) or zonisamide (ZNS) was demonstrated by functional MRI (fMRI) and current-source density of electroencephalogram (EEG) [38, 39] . Because TPM and ZNS have multiple modes of action including GABAergic activity, we suggest any AED affecting these regions can cause apathy as well as cognitive dysfunction. Our study demonstrated that only long-term users of AEDs produced apathy. Therefore, fMRI or EEG studies to compare functional changes of the brain between short-term and the longterm users of AEDs should be warranted in the future.
There are some limitations of the study. First, eligible participants were recruited at a tertiary care hospital and predictors of apathy may differ between this population and the community population of PWE. Second, we evaluated apathy with the AES-S. The degree of apathy may be accentuated with the AES-I because caregivers are more likely to be sensitive to apathy than patients [40] . However, due to felt stigma, PWE usually visit alone in outpatient clinic without accompanying persons. In that case, we have no choice but to use a self-assessment tool. Third, although most of the healthy controls were not related to the patients, some controls had personal relationships with the patients. Therefore, their emotion may be contaminated by patients. In this context, the difference of apathy between patients and controls can be increased. Fourth, because this study is a crosssectional study, it only captures a specific point in time and it is consequently difficult to analyze changes within a certain period of time. Therefore, a longitudinal study to observe the change of motivation during AED intake or after stopping AEDs is needed. Fifth, in a case-control study, an important technique for adding power to a study is to enroll more than one control for every case. However, the number of controls was less than that of patients in our study. So the meaning of the results can be faded because of the weak statistical power. We found that apathetic PWE had poor QOL and, therefore, need appropriate management. First, we should ask about the lack of effort and passive activities to the patients or their caregivers, and if suspected, conduct screening tools for depression and apathy. Second, if severe epilepsy patients can be remedied by other therapeutic interventions including epilepsy surgery, we should consider them instead of medication. Third, if patients cannot stop AEDs, we can consider antidepressants for depression, and dopaminergic agents or psychostimulants for apathy [2, 32] . Fourth, education about apathy and suggestions of practical strategies including a regular daily routine with more varied activities, getting out of the house every day, and encouraging caregivers to take up regular respite care without guilt may reduce its impact on daily living [2] . Of course, further studies should be conducted whether these interventions are effective in PWE as in AD or other neurological disorders.
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